What is preventing the French pharmaceutical group and U.S. biotech from reaching a merger agreement?
Continue reading Still No Deal Between Sanofi-Aventis and Genzyme
Still No Deal Between Sanof…
Lpath focuses on developing therapeutics that target bioactive lipids for treating a range of human diseases, including cancer and diseases that cause blindness. Its promising drugs have attracted attention — and lots of money…
The path to profits for most of Corporate America lately has been cutting costs rather than raising revenue. But a careful look reveals a few companies that are poised to deliver real revenue growth. We’ve found six with a plus…
If you’ve been to a supermarket lately, you’ve probably noticed that food prices are soaring. And that spells an opportunity for investors. Asset-management expert John Stephenson offers tips for small investors aiming to tap i…
Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting — if not always positive — year. Here’s our rundown of the…